Efficacy and Safety of Doxycycline in the Treatment of Children with Azithromycin Resistant Mycoplasma Pneumonia
Objective:To explore the efficacy and safety of doxycycline in the treatment of children with azithromycin resistant my-coplasma pneumonia(MPP).Methods:A total of 138 children with MPP who were hospitalized and treated in the Department of Pediatrics of our hospital from February 2022 to February 2024 were enrolled and divided into a treatment group(n=69)and a reference group(n=69)according to the random number table method.Azithromycin dry suspension was administered for 72 hours in both groups,azithromycin dry suspension was continued in the reference group,and doxycycline tablets were administered in the treatment group.The clinical efficacy and adverse reactions of the two groups were compared.The inflammatory biochemical indexes[D-dimer(D-D),C-reactive protein(CRP)]were compared before and after treatment.The symptom relief time was compared between the two groups.Results:Compared with the effective rate of the reference group(68.12％),the clinical effective rate of the treatment group(98.55％)was higher(P＜0.05).Compared before treatment,the inflammatory biochemical indexes D-D and CRP in the two groups decreased after treatment,and the improvement in the treatment group was better than that in the reference group(P＜0.05).Compared with the reference group,the treatment group had significantly shorter time to cough relief,body temperature recovery,and pulmonary rales disappearance(P＜0.05).Compared with the reference group(11.59％),the incidence of adverse reactions in the treatment group(1.45％)was lower(P＜0.05).Conclusion:Doxycycline is effective in the treatment of children with azithromycin resistant MPP,which is beneficial to alleviate the inflammatory state of the body and reduce the time to symptom relief.The incidence of adverse reactions is low in the short term,which provides a reference for clinical decision-making and the rea-sonable choice of antibiotics.However,in view of the lack of evidence and experience for the use of antibiotics in children,evidence-based evidence for off-label use needs to be continuously accumulated to provide reference for clinical decision-making and rational selection of antibiotics.
万方数据
维普
